Norcliffe Capital Ltd FRN # 826977 who is an Appointed Representative of Sturgeon Ventures LLP who is authorised and regulated by the Financial Conduct Authority FRN # 452811.
Biosceptre International Limited is a UK-based biopharmaceutical company pioneering the development of a CAR-T therapy for the treatment of a broad range of cancers.
The company has identified a unique target, nfP2X7, which is found only on cancer cells, but not on normal cells. This target will be used by state-of-the-art immunotherapies to specifically target and kill the cancer cells, whilst leaving normal cells unaffected. This should avoid the potential for unpleasant side effects currently associated with the treatment of cancer.
The company has a world class leadership team with the Scientific Advisory Board led by Sir Greg Winter, winner of the Nobel Prize for Chemistry 2018.
Norcliffe Capital raised £6 million on behalf of Biosceptre to progress its CAR-T development program, including IND enabling preclinical and first in man studies for its haematological, solid tumour and monoclonal antibody programs.
Biosceptre has a pre-money valuation of £271 million and a forecasted valuation in 2025 between £3 billion and £14 billion.
Afon Technology Limited is developing a non- invasive continual blood glucose monitoring device that delivers results in real-time, enhancing the take up and quality of daily management programs for diabetics.
Norcliffe Capital has raised £3.3m of investment on behalf of Afon Technology enabling the Company to enter the final 12 months of development prior to CE marking.
Recent trials in a world leading diabetes clinical centre in Germany have demonstrated the efficacy of the technology with performances on par to those achieved with commercial invasive devices.
Afon is seeking to raise a further £5,000,000 to develop the device ready for CE marking and FDA approval. Afon Technology has a forecasted valuation in 2022 between £50 million and £100 million.
NeedleSmart Limited has developed market-leading technology to sterilise and destroy hypodermic needles. The needle is heated to 1300 degrees and compressed into a sphere, creating a non-sharp and negating the use of sharps bins. The device addresses two issues: preventing needlestick injuries and reducing disposal costs by up to 80%.
The device also collects data to facilitate a seamless record and reordering system for patients and practitioners. The handheld device for diabetics will also provide reminders and compliance data, to enable clinicians to fine tune a patient’s therapy.
Norcliffe Capital has raised £9 million of equity on behalf of NeedleSmart to develop the family of devices, achieve CE mark and FDA approval before commencing global sales.
Dxcover has developed a cancer diagnostic system using simple blood test analysis. It employs infrared spectroscopy coupled with machine learning, artificial intelligence to recognise molecular changes associated with specific cancers in a blood sample.
The first clinical evaluations have been published in leading medical journals and the system is protected by strong IP. This revolutionary and simple, “drop, dry, detect” system has the potential to save lives through early and cost-effective diagnosis.
Dxcover’s second round of funding will enable them to develop their technology into a multi cancer blood test which could pick up 65% of all cancers. The technology can be extended to other diseases by training new diagnostic algorithms.
Dxcover uses standard spectroscopy techniques which means their test could be conducted in hospitals and GP surgeries rather than using specialist laboratories. Indeed, Dxcover’s technology could be used as a precautionary cancer screening tool which can lead on to more expensive DNA testing if needed.
Dxcover’s objective is to detect cancers early before symptoms become obvious which will save lives. Dxcover has a current valuation of £9.03 million and a forecasted valuation in 2025 of over £100 million.
Wi-Fi Securities Limited has developed an innovative IP protected system called SpriteGuard™.
The SpriteGuard™ system:
The SpriteGuard™ system scans and detects all wireless hotspots within the surrounding area and all devices connected to them (mobile phone, laptop, tablet, etc.) for illegitimate Wi-Fi hotspots. If a device accidently connects to an illegitimate hotspot SpriteGuard™ stops the connection being made and redirects the device to the correct and legitimate hotspot.
The device also provides significant spatial analytic data to help companies identify how their environment is used.
Norcliffe Capital has raised £1.5 million to date. Wi-Fi Securities require a further £3.5 million to take the system from MVP to final product development, through CE mark and into the market by early 2022.
SMi Drug Discovery has developed a transformational, new, optical technology that will have far-reaching benefits in the fields of diagnosis and drug discovery. SMi’s technology is a variant of super resolution microscopy, an area which was the subject of Nobel Prizes in 2014 and 2017. SMi have been awarded a non-dilutive £1.9M UK Innovation grant for the development of their platform for virus diagnosis in large central laboratories.
The system can identify and count individual virus in a sample in 50 milliseconds, with a sensitivity equivalent to the gold standard PCR tests. SMi’s technology complements Aurem’s in that is designed for large central locations.
SMi’s platform’s second application is in speeding up drug discovery where cutting a year off development can save > $100 million. During drug development, scientists need to know how a drug binds to its target, exactly where and for how long. SMi’s technology is revolutionary as it can visualise hundreds of thousands of these interactions whereas current techniques provide only average data. A good analogy is that current techniques are like trying to determine the exact composition of traffic from the noise of vehicles whereas, SMi’s technology photographs and counts every bus, car, lorry and bike.
The Company is raising £3.64 million for 39.6% equity, at a pre-money valuation of £4 million. Potential investor returns are 8x to 16x.
Medical diagnosis is about to undergo a revolution based on the next generation of cheap, mass manufacturable, electrochemical sensors like those to check blood sugar levels in people with diabetes. Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde and is based on the work of Dr Corrigan and his team.
The team have already demonstrated the ability of their electrochemical platform to detect COVID in 2 minutes and to detect critical markers of sepsis, where a one hour delay in diagnosis can result in a 10% increase in mortality. The platform is ideally suited for rapid diagnosis of many conditions at the point of care and for the rapid diagnosis of COVID in sites like travel hubs, schools, workplaces and at home.
The Company requires £3.51 million for a total investor shareholding of 75.6% of the Company, at a pre-money valuation of £1.13 million to develop two types of readers: highly sensitive impedimetric readers and cheaper amperometric readers which use similar technology to glucose monitoring strips. Potential investor returns are 7x to 15x.